# Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older

> **NCT04537234** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 165 (actual)

## Conditions studied

- Influenza (Healthy Volunteers)

## Interventions

- **BIOLOGICAL:** High-Dose Quadrivalent Influenza Vaccine
- **BIOLOGICAL:** Standard-Dose Quadrivalent Influenza Vaccine

## Key facts

- **NCT ID:** NCT04537234
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-10
- **Primary completion:** 2021-02-09
- **Final completion:** 2021-02-09
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04537234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04537234, "Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04537234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*